Biogen Inc (BIIB)

Add to Watchlists
Create an Alert
Quickflows
264.11 -2.49  -0.93% NASDAQ Mar 4, 16:11 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All BIIB News

News

View All Events

Events

Date Type Description
04/22/2021 Earnings Biogen Inc First Quarter Earnings Results for 2021
04/22/2021 Misc Biogen Inc First Quarter Earnings Conference Call for 2021
02/03/2021 Earnings Biogen Inc Fourth Quarter Earnings Result for 2020
02/03/2021 08:00 EST Misc Biogen Inc Fourth Quarter Earnings Conference Call for 2020
02/03/2021 Misc Biogen Inc Annual Report for 2020
10/21/2020 Earnings Biogen Inc Third Quarter Earnings Result for 2020
10/21/2020 08:00 EDT Misc Biogen Inc Third Quarter Earnings Conference Call for 2020
07/22/2020 08:00 EDT Misc Biogen Inc Second Quarter Earnings Conference Call for 2020
07/22/2020 Earnings Biogen Inc Second Quarter Earnings Result for 2020
06/03/2020 09:00 EDT Misc Biogen Inc Annual General Meeting for 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 13.44B
Total Expenses (TTM) 8.998B
Net Income (TTM) 4.001B

Balance Sheet View Statement

Total Assets (Quarterly) 24.62B
Total Liabilities (Quarterly) 13.93B
Shareholders Equity (Quarterly) 10.70B

Cash Flow Statement View Statement

Cash from Operations (TTM) 4.230B
Cash from Investing (TTM) -608.60M
Cash from Financing (TTM) -5.273B

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.biogen.com
  • Investor Relations URL: https://www.biogen.com/en_us/investors.html
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Apr. 22, 2021
  • Last Earnings Release: Feb. 03, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 264.11
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
LMPFX ClearBridge Aggressive Growth FI 5.41%
PKW Invesco BuyBack Achievers ETF 5.23%
FBT First Trust NYSE Arca Biotech ETF 3.50%
IBB iShares Nasdaq Biotechnology ETF 3.45%
FBIOX Fidelity® Select Biotechnology 3.33%
VPMCX Vanguard PRIMECAP Inv 3.18%
VHCOX Vanguard Capital Opportunity Inv 2.59%
VPCCX Vanguard PRIMECAP Core Inv 2.43%
MOAT VanEck Vectors Morningstar Wide Moat ETF 2.36%
FXH First Trust Health Care AlphaDEX® ETF 2.20%
VGHCX Vanguard Health Care Inv 2.11%
XBI SPDR® S&P Biotech ETF 1.00%

Comparables

Edit
SAGE Sage Therapeutics Inc
LLY Eli Lilly and Co
GILD Gilead Sciences Inc
ICPT Intercept Pharmaceuticals Inc
NERV Minerva Neurosciences Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.